BOSTON, MA, USA I April 18, 2023 I Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its SNS-103 program aimed at developing a conditionally active, monoclonal antibody program targeting ENTPDase1 (also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023.
“CD39 is an important target because it is the rate-limiting enzyme that creates an immunosuppressive tumor microenvironment through the production of adenosine. However, it has been difficult to target effectively due to its broad expression on various cells in both tumors and normal tissues,” said Edward van der Horst, Ph.D., Chief Scientific Officer at Sensei Biotherapeutics. “The hypothesis driving our program is that a pH-sensitive antibody may inhibit the pro-tumoral activities of CD39 selectively within the tumor microenvironment while avoiding on-target/off-tumor binding and pharmacokinetic issues observed with prior CD39 antibodies.”
Presentation highlights:
Poster presentation titled, “Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironment”
- CD39 is commonly upregulated in the tumor microenvironment, which is characterized by high levels of extracellular ATP (eATP) and low pH. Upregulation and activation of CD39 results in significant reductions of eATP and a rise in immunosuppressive adenosine.
- SNS-103 is aimed at developing an antibody that binds to CD39 only under low pH conditions such as those found in the tumor microenvironment and achieves a high target occupancy selectively in the tumor, while maintaining extracellular ATP and inhibiting adenosine generation to enhance anti-tumor immunity.
- From a panel of 83 antibodies identified and characterized for CD39 inhibition at neutral and acidic pH, Sensei has selected 8 antibodies for further optimization.
- Sensei intends to select a lead product candidate for SNS-103 in 2023.
The full poster is available for viewing on Sensei’s corporate website.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
SOURCE: Sensei Biotherapeutics
Post Views: 337
BOSTON, MA, USA I April 18, 2023 I Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its SNS-103 program aimed at developing a conditionally active, monoclonal antibody program targeting ENTPDase1 (also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023.
“CD39 is an important target because it is the rate-limiting enzyme that creates an immunosuppressive tumor microenvironment through the production of adenosine. However, it has been difficult to target effectively due to its broad expression on various cells in both tumors and normal tissues,” said Edward van der Horst, Ph.D., Chief Scientific Officer at Sensei Biotherapeutics. “The hypothesis driving our program is that a pH-sensitive antibody may inhibit the pro-tumoral activities of CD39 selectively within the tumor microenvironment while avoiding on-target/off-tumor binding and pharmacokinetic issues observed with prior CD39 antibodies.”
Presentation highlights:
Poster presentation titled, “Identification of conditionally active antibodies that selectively block CD39 activity in the acidic tumor microenvironment”
- CD39 is commonly upregulated in the tumor microenvironment, which is characterized by high levels of extracellular ATP (eATP) and low pH. Upregulation and activation of CD39 results in significant reductions of eATP and a rise in immunosuppressive adenosine.
- SNS-103 is aimed at developing an antibody that binds to CD39 only under low pH conditions such as those found in the tumor microenvironment and achieves a high target occupancy selectively in the tumor, while maintaining extracellular ATP and inhibiting adenosine generation to enhance anti-tumor immunity.
- From a panel of 83 antibodies identified and characterized for CD39 inhibition at neutral and acidic pH, Sensei has selected 8 antibodies for further optimization.
- Sensei intends to select a lead product candidate for SNS-103 in 2023.
The full poster is available for viewing on Sensei’s corporate website.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
SOURCE: Sensei Biotherapeutics
Post Views: 337
